Lataa...
厄洛替尼治疗晚期非小细胞肺癌分类及回归树分析
BACKGROUND AND OBJECTIVE: Erlotinib is a targeted therapy drug for non-small cell lung cancer (NSCLC). It has been proven that, there was evidence of various survival benefits derived from erlotinib in patients with different clinical features, but the results are conflicting. The aim of this study...
Tallennettuna:
| Julkaisussa: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
中国肺癌杂志编辑部
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5999942/ https://ncbi.nlm.nih.gov/pubmed/22008108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2011.10.04 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|